Literature DB >> 22613501

Tissue Doppler systolic velocity change during dobutamine stress echocardiography predicts contractile reserve and exercise tolerance in patients with heart failure.

Quirino Ciampi1, Lorenza Pratali, Michele Della Porta, Bruno Petruzziello, Vincenzo Manganiello, Bruno Villari, Eugenio Picano, Rosa Sicari.   

Abstract

AIMS: Dobutamine stress echocardiography (DSE) is widely used to evaluate myocardial contractile reserve in patients with heart failure (HF). The aim of the study was to assess the relationship between the tissue Doppler (TD) mitral annulus systolic velocity (Sm) change during DSE, contractile reserve, and aerobic exercise capacity in HF patients. METHODS AND
RESULTS: Sixty-four HF patients (age 67 ± 9 years, 58% with an ischaemic aetiology, and a mean value of the ejection fraction 29 ± 7%) underwent high-dose DSE. The mean value of the TD mitral annulus septal-lateral Sm change was analysed at rest and at peak DSE. All patients underwent also the cardiopulmonary exercise test. With a receiver operating characteristic analysis, a value of 2.02 cm/s obtained as a stress-rest difference in a mean value of the peak systolic velocity of the mitral annulus (Sm) was the best value for diagnosing the myocardial contractile reserve [area under the curve 0.69 (95% CI 0.56-0.80), sensitivity 69% (95% CI 54-81), specificity 80% (95% CI 45-97)]. The patient population was divided into two groups: with rest-stress Sm change during DSE ≤ 2.02 cm/s and with rest-stress Sm change >2.02 cm/s. Patients with Sm rest-stress >2.02 change during DSE, compared with patients with rest-stress change ≤2.02, showed a lower incidence of severe diastolic dysfunction at rest (16 vs. 46%, P= 0.039) and lower E/Ea values (11 ± 5 vs. 15 ± 6, P = 0.005), similar ejection fraction at rest but higher ejection fraction at peak DSE (53 ± 14 vs. 41 ± 12%, P = 0.001), better myocardial contractile reserve assessed by a pressure-volume relationship (1.89 ± 2.01 vs. 0.58 ± 1.38 mmHg/mL/m(2), P = 0.004), with a lower end-systolic volume (-46 ± 20 vs. -24 ± 19%, P< 0.001), a higher increase in the ejection fraction (23 ± 10 vs. 12 ± 10%, P = 0.001) during DSE, and better peak oxygen consumption (16 ± 4 vs. 13 ± 2 mL/kg/min, P = 0.01).
CONCLUSION: In patients with HF, the rest-stress variation of mitral annulus systolic velocities during DSE predicts the presence of myocardial contractile reserve and exercise tolerance.

Entities:  

Mesh:

Year:  2012        PMID: 22613501     DOI: 10.1093/ehjci/jes096

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  4 in total

1.  Prognostic importance of tissue velocity imaging during exercise echocardiography in patients with systolic heart failure.

Authors:  Jet van Zalen; Nikhil R Patel; Steven J Podd; Prashanth Raju; Rob McIntosh; Gary Brickley; Louisa Beale; Lydia P Sturridge; Guy W L Lloyd
Journal:  Echo Res Pract       Date:  2015-03-03

2.  Different determinants of exercise capacity in HFpEF compared to HFrEF.

Authors:  Arlind Batalli; Pranvera Ibrahimi; Ibadete Bytyçi; Artan Ahmeti; Edmond Haliti; Shpend Elezi; Michael Y Henein; Gani Bajraktari
Journal:  Cardiovasc Ultrasound       Date:  2017-04-26       Impact factor: 2.062

3.  Left ventricular markers of global dyssynchrony predict limited exercise capacity in heart failure, but not in patients with preserved ejection fraction.

Authors:  Gani Bajraktari; Arlind Batalli; Afrim Poniku; Artan Ahmeti; Rozafa Olloni; Violeta Hyseni; Zana Vela; Besim Morina; Rina Tafarshiku; Driton Vela; Premtim Rashiti; Edmond Haliti; Michael Y Henein
Journal:  Cardiovasc Ultrasound       Date:  2012-09-11       Impact factor: 2.062

4.  Gender related predictors of limited exercise capacity in heart failure.

Authors:  Gani Bajraktari; Ilir Kurtishi; Nehat Rexhepaj; Rina Tafarshiku; Pranvera Ibrahimi; Fisnik Jashari; Rrezarta Alihajdari; Arlind Batalli; Shpend Elezi; Michael Y Henein
Journal:  Int J Cardiol Heart Vessel       Date:  2013-10-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.